364
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor: Clinical Oncology

Radio-induced lung injury after breast helicoidal tomotherapy: long term safety

&
Pages 942-943 | Received 10 Apr 2023, Accepted 06 Jul 2023, Published online: 01 Aug 2023

References

  • Lind PA, Wennberg B, Gagliardi G, et al. Pulmonary complications following different radiotherapy techniques for breast cancer, and the association to irradiated lung volume and dose. Breast Cancer Res Treat. 2001;68(3):199–210. doi:10.1023/A:1012292019599.
  • Lind PA, Wennberg B, Gagliardi G, et al. ROC curves and evaluation of radiation-induced pulmonary toxicity in breast cancer. Int J Radiat Oncol *Biol *Phys. 2006;64(3):765–770. doi:10.1016/j.ijrobp.2005.08.011.
  • Gokula K, Earnest A, Wong LC. Meta-analysis of incidence of early lung toxicity in 3-dimensional conformal irradiation of breast carcinomas. Radiat Oncol. 2013;8(1):268. doi:10.1186/1748-717X-8-268.
  • Lee BM, Chang JS, Kim SY, et al. Hypofractionated radiotherapy dose scheme and application of new techniques are associated to a lower incidence of radiation pneumonitis in breast cancer patients. Front Oncol. 2020;10:124. doi:10.3389/fonc.2020.00124.
  • Zhou Z-R, Han Q, Liang S-X, et al. Dosimetric factors and lyman normal-tissue complication modelling analysis for predicting radiation-induced lung injury in postoperative breast cancer radiotherapy: a prospective study. Oncotarget. 2017;8(20):33855–33863. doi:10.18632/oncotarget.12979.
  • Bentzen SM, Skoczylas JZ, Overgaard M, et al. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst. 1996;88(13):918–922. doi:10.1093/jnci/88.13.918.
  • Koc M, Polat P, Suma S. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol. 2002;64(2):171–175. doi:10.1016/S0167-8140(02)00136-6.
  • Gueiderikh A, Sarrade T, Kirova Y, et al. Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors. Front Oncol. 2023;13:1199043. doi:10.3389/fonc.2023.1199043.
  • Schubert LK, Gondi V, Sengbusch E, et al. Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy. Radiother Oncol. 2011;100(2):241–246. doi:10.1016/j.radonc.2011.01.004.
  • Hijal T, Fournier- Bidoz N, Castro-Pena T, et al. Simultaneous integrated boost in breast conserving treatment of breast cancer: a dosimetric comparison of helical tomotherapy and three-dimensional conformal radiotherapy. Radiother Oncol. 2010;94(3):300–306. doi:10.1016/j.radonc.2009.12.043.
  • Goddu SM, Chaudhari S, Mamalui-Hunter M, et al. Helical tomotherapy planning for Left-Sided breast cancer patients with positive lymph nodes: comparison to conventional multiport breast technique. Int J Radiat Oncol Biol Phys. 2009;73(4):1243–1251. doi:10.1016/j.ijrobp.2008.11.004.
  • Cendales R, Schiappacasse L, Schnitman F, et al. Helical tomotherapy in patients with breast cancer and complex treatment volumes. Clin Transl Oncol. 2011;13(4):268–274. doi:10.1007/s12094-011-0652-7.
  • Arsene-Henry A, Foy JP, Robillard M, et al. The use of helical tomotherapy in the treatment of early stage breast cancer: indications, tolerance, efficacy—a single center experience. Oncotarget. 2018;9(34):23608–23619. doi:10.18632/oncotarget.25286.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.